The 5 Activist Filings to Watch This Week: June 30–July 6, 2026
Executive summary: The 5 highest-signal activist filings for the week of June 30–July 6, 2026 are Sands Capital in Alamar Biosciences (ALMR), Legion Partners in Lifecore Biomedical (LFCR), Franklin Resources in Franklin BSP Lending Fund, Legion Partners in NN, Inc. (NNBR), and Fairmount Funds in Oruka Therapeutics (ORKA). All five are 13D/A amendments, ranked by insider buying, institutional overlap, short-interest days-to-cover, and activist clustering.
This is the first edition of a new weekly format. Every Monday, 13dwatch will publish the prior week's 5 highest-signal filings made under Securities and Exchange Commission (SEC) Schedule 13D and 13G, computed the same way: not by dollar size alone, but by a composite signal that layers insider Form 4 activity, institutional consensus among 10 tracked elite managers, Financial Industry Regulatory Authority (FINRA) short interest, and multi-activist clustering on top of the underlying stake. This edition covers Monday, June 30 through Sunday, July 6, 2026 — 18,915 activist filings and 88,900 insider transactions deep in the underlying database as of this writing, per 13dwatch's public health endpoint.
Methodology
The ranking is produced by 13dwatch's live filing-and-signal pipeline, not a manual read of headlines. The system pulls Schedule 13D/13D-A/13G/13G-A filings, joins each to Form 4 insider transactions (matched on issuer CIK, excluding self-filed insiders who are also the activist), joins to a 10-manager institutional consensus view (Berkshire, Pershing Square, Baupost, Appaloosa, Third Point, Duquesne, Viking, Tiger Global, Greenlight, Lone Pine), and joins to FINRA short-interest data on ticker. Each filing gets points for: filing recency, presence of insider buying, number of elite-manager holders, short-interest days-to-cover above 5 and above 10, the number of distinct activists filing on the same issuer within a trailing 90 days, whether the filing is an initial 13D versus an amendment, and stake size at the 5% and 10% thresholds. The system tries a 48-hour window first and falls back to 14 days if fewer than 5 filings clear the bar; this week the fallback produced a clean match to the calendar week of June 30–July 6.
One disclosure worth stating plainly: all 5 filings in this edition are Schedule 13D/A amendments, not new initial Schedule 13D filings. That is not a data-quality issue — it reflects the SEC's own rule requiring 13D amendments within 2 business days of a material change, which means amendment-stage filings carry the same urgency as an initial filing and often disclose the exact moment a stake crossed a new threshold or a second activist joined an existing situation.
This week's 5 highest-signal filings
| Rank | Filer → Issuer (ticker) | Form | Filed | Stake | Signals present |
|---|---|---|---|---|---|
| 1 | Sands Capital Life Sciences Pulse Fund II, L.P. → Alamar Biosciences, Inc. (ALMR) | 13D/A | 2026-07-05 | 6.10% (4,230,926 sh) | 2 insider buys · short-interest days-to-cover 11.5 · 2 activists on issuer in 90d |
| 2 | Legion Partners Asset Management, LLC → Lifecore Biomedical, Inc. (LFCR) | 13D/A | 2026-06-30 | 17.10% (6,196,557 sh) | 1 elite-manager holder · DTC 12.3 · 2 activists in 90d |
| 3 | Franklin Resources Inc → Franklin BSP Lending Fund | 13D/A | 2026-07-06 | 68.70% (75,000 sh) | 6 activists on issuer in 90d |
| 4 | Legion Partners Asset Management, LLC → NN, Inc. (NNBR) | 13D/A | 2026-07-02 | not disclosed in this filing | 1 elite-manager holder · DTC 4.6 · 3 activists in 90d |
| 5 | Fairmount Funds Management LLC → Oruka Therapeutics, Inc. (ORKA) | 13D/A | 2026-07-01 | 19.50% (14,553,895 sh) | 2 elite-manager holders · DTC 6.1 |
Each filing's SEC EDGAR index: Alamar/Sands Capital, Lifecore/Legion Partners, Franklin BSP Lending Fund/Franklin Resources, NN Inc/Legion Partners, Oruka/Fairmount Funds.
Approximate signal-score breakdown
The table below reconstructs each filing's score components from the badges the ranking system attaches — a narrative breakdown, not a re-execution of the underlying scoring function, since no single numeric score is exposed publicly.
| Filing | Recency | Insider buying | Institutional overlap | Short interest | Activist clustering | Stake size | Approx. total |
|---|---|---|---|---|---|---|---|
| Alamar (ALMR) | +1 | +7 | 0 | +5 | +4 | +1 | 18 |
| Lifecore (LFCR) | 0 | 0 | +3 | +5 | +4 | +2 | 14 |
| Franklin BSP Lending Fund | +1 | 0 | 0 | 0 | +8 | +2 | 11 |
| NN Inc (NNBR) | +1 | 0 | +3 | 0 | +5 | 0 | 9 |
| Oruka (ORKA) | 0 | 0 | +4 | +3 | 0 | +2 | 9 |
10 findings from this week's list
- Every filing this week is an amendment (13D/A), not an initial 13D — a reminder that the highest-signal activity in any given week often comes from position changes on existing situations, not brand-new campaigns.
- Alamar Biosciences carries the only insider-buying signal in the group: 2 open-market purchases alongside Sands Capital's amended stake, the combination that produces the highest composite score this week.
- Four of the 5 issuers (Alamar, Lifecore, Franklin BSP Lending Fund, NN Inc) show 2 or more activists filing within a trailing 90 days — the "wolf pack" pattern tracked in 13dwatch's clustering study. Oruka Therapeutics is the only issuer this week without a multi-activist cluster.
- Franklin BSP Lending Fund shows the heaviest clustering of the week at 6 distinct activist filers in 90 days, despite carrying no insider or short-interest signal — its high rank is driven entirely by that clustering plus a 68.70% stake.
- Legion Partners Asset Management appears twice this week, in Lifecore Biomedical and NN, Inc. — both mid-cap industrials/healthcare names with existing multi-activist attention.
- Days-to-cover ranges from 4.6 (NN Inc) to 12.3 (Lifecore Biomedical) across the filings with short-interest data attached; a DTC above 10 (Lifecore, Alamar) flags meaningfully crowded short positioning layered under an active 13D situation.
- NN, Inc.'s filing does not disclose a parsed stake percentage in the underlying data, though the share count (3,733,515) is present — a gap in this specific filing's structured fields, not a system-wide issue.
- None of the 5 filings this week carry a high-signal AI-classified intent tag (strategic, M&A-arbitrage, board-change, capital-structure, or distressed) in the underlying data, meaning the ranking this week rests entirely on the quantitative signals in Finding 1 through 7, not qualitative purpose-language classification.
- The trailing-week window used here (June 30–July 6) results from a 48-hour-then-14-day fallback in the ranking system, not a strict calendar-week query — future weekly editions will explicitly bound the query to the prior Monday–Sunday range.
- Two of the five filers (Sands Capital, Fairmount Funds) are healthcare/biotech-focused activists — consistent with the sector concentration flagged in 13dwatch's activist sector-rotation study.
Frequently Asked Questions
What counts as a "highest-signal" activist filing?
A filing scores higher when it combines a meaningful stake (5%+ or 10%+) with additional signals: insider Form 4 buying at the same issuer, overlap with one or more of 10 tracked elite institutional managers, elevated FINRA short-interest days-to-cover, or multiple activists filing on the same issuer within 90 days. A large stake alone does not guarantee a high rank.
Why are all 5 filings this week amendments (13D/A) instead of new 13D filings?
The SEC requires Schedule 13D amendments within 2 business days of a material change (SEC fact sheet), so amendment-stage filings can carry the same urgency as an initial filing — a stake crossing a new threshold, or a second activist joining an existing situation, both trigger an amendment rather than a new 13D.
How often is this list updated?
This is the first edition of a weekly format intended to publish every Monday, covering the prior Monday-through-Sunday window of activist filings.
Where does the underlying data come from?
Schedule 13D/13G filings and Form 4 insider transactions are sourced directly from SEC EDGAR; institutional consensus is derived from 13F filings for 10 named elite managers; short-interest data comes from FINRA's semi-monthly short-interest release. See 13dwatch's methodology for the full pipeline.
Does a high signal score mean a stock is a buy?
No. This is a ranking of filing-level signal density for research purposes, not a trading recommendation. See the disclaimer below.
What this means for hedge fund and RIA research desks
A single Schedule 13D filing rarely tells the whole story. This week's list shows why: Franklin BSP Lending Fund's 68.70% stake looks like the headline number, but its actual ranking driver is 6 activists circling the same issuer in 90 days — a pattern invisible if you're reading filings one at a time instead of scoring them against a consistent, cross-referenced signal set. For a research desk without a pipeline that joins 13D, Form 4, 13F, and short-interest data, reconstructing this view manually each week means pulling four separate sources and cross-referencing tickers by hand.
Get the live, continuously updated version of this signal at 13dwatch.com — $1,500/month, full API access.
This post is research based on public SEC and FINRA filings, not investment advice. 13dwatch and Long Street Consulting LLC do not recommend any security named above. Data as of 2026-07-09; stake percentages and share counts reflect the referenced filing's disclosure date, not current ownership.